A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection
Authors
Keywords
-
Journal
PHARMACOECONOMICS
Volume 35, Issue 11, Pages 1123-1140
Publisher
Springer Nature
Online
2017-09-06
DOI
10.1007/s40273-017-0540-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
- (2016) Maureen Watt et al. INFECTION
- Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire
- (2016) Kevin W. Garey et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Clostridium difficile infection: Early history, diagnosis and molecular strain typing methods
- (2016) C. Rodriguez et al. MICROBIAL PATHOGENESIS
- Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection
- (2016) Lauren Lapointe-Shaw et al. PLoS One
- Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production
- (2016) Caroline H. Chilton et al. PLoS One
- Recurrent Clostridium difficile infection: From colonization to cure
- (2015) Kelsey Shields et al. ANAEROBE
- Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection
- (2015) Jason C. Gallagher et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations
- (2015) S. D. Goldenberg et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain
- (2015) C. Rubio-Terrés et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital
- (2015) S. M. Heimann et al. INFECTION
- Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin
- (2015) Seth T. Housman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- The Morbidity, Mortality, and Costs Associated with Clostridium difficile Infection
- (2015) Jennie H. Kwon et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- A Cost-effectiveness and Budget Impact Analysis of Fidaxomicin for Treating Clostridium Difficile Patients In Germany
- (2015) M. Watt et al. VALUE IN HEALTH
- Cost-Effectiveness Analysis of Vancomycin Versus Metronidazole for Management Of Initial Episodes of Clostridium difficile Infection in Hospitalized Patients
- (2015) Diana Karkow et al. Open Forum Infectious Diseases
- Thresholds for the cost–effectiveness of interventions: alternative approaches
- (2015) Elliot Marseille et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis
- (2014) Gauree G. Konijeti et al. CLINICAL INFECTIOUS DISEASES
- Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection
- (2014) R.U. Varier et al. CLINICAL MICROBIOLOGY AND INFECTION
- 473
- (2014) Punit Singh et al. CRITICAL CARE MEDICINE
- Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison
- (2014) Oliver A. Cornely et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
- (2014) D. Nathwani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Update on Clostridium difficile infections
- (2014) A. Le Monnier et al. MEDECINE ET MALADIES INFECTIEUSES
- Cost-Utility Analysis Of Fidaxomicin Compared To Vancomycin In The Management Of Severe Clostridium Difficile Infection In Poland
- (2014) P. Petryszyn et al. VALUE IN HEALTH
- Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infections (CDI) also Known as Clostridium Difficile-Associated Diarrhoea (CDAD) in Spain
- (2014) J. Cobo Reinoso et al. VALUE IN HEALTH
- Cost-Effectiveness of Fidaxomicin Therapy for Clostridium Difficile Infection in Hungary
- (2014) V. Brodszky et al. VALUE IN HEALTH
- Cost-Effectiveness of Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) in Sweden
- (2014) A. Van Engen et al. VALUE IN HEALTH
- Cost-Effectiveness Of Various Clostridium Difficile Infection (CDI) Treatments In Patients With Recurrent Infections
- (2014) S. Massachi et al. VALUE IN HEALTH
- Cost-effectiveness analysis of treatment strategies for initial clostridium difficile infection
- (2014) E. Biltaji et al. VALUE IN HEALTH
- Economic Evaluation Of Fidaxomicin Compared With Vancomycin In The Treatment Of Clostridium Difficile Infection
- (2014) C McCrea et al. VALUE IN HEALTH
- Guidelines for Diagnosis, Treatment and Prevention of Clostridium difficile Infections
- (2013) Christina M Surawicz et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Is Fidaxomicin Worth the Cost? An Economic Analysis
- (2013) Sarah M. Bartsch et al. CLINICAL INFECTIOUS DISEASES
- The Cost-Utility of Fidaxomicin as Compared to Current Standard Treatment in the Management of Clostridium Difficile Infections in Belgium
- (2013) M. Lamotte et al. VALUE IN HEALTH
- Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infections (CDI) also known as C. Difficile-Associated Diarrhoea (CDAD) in Ireland
- (2013) A. Van Engen et al. VALUE IN HEALTH
- Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States
- (2013) Paul M. Stranges et al. VALUE IN HEALTH
- Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance
- (2013) Kathleen Mullane Therapeutic Advances in Chronic Disease
- Fidaxomicin Inhibits Spore Production in Clostridium difficile
- (2012) Farah Babakhani et al. CLINICAL INFECTIOUS DISEASES
- Consequences of Clostridium difficile infection: understanding the healthcare burden
- (2012) E. Bouza CLINICAL MICROBIOLOGY AND INFECTION
- Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence
- (2012) Konstantinos Z. Vardakas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection
- (2012) P.N. Wiegand et al. JOURNAL OF HOSPITAL INFECTION
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- PIN35 Decision Analysis Model Evaluating the Cost-Effectiveness of Fidaxomicin and Vancomycin in the Treatment of Clostridium Difficile Infection (CDI) from a Hospital Perspective
- (2012) M.S. Alowayesh et al. VALUE IN HEALTH
- PGI21 a Comparison of the Cost-Effectiveness of Fidaxomicin, Metronidazole, and Vancomycin, in the Treatment of Clostridium Difficile-Associated Disease
- (2012) N. Madkour et al. VALUE IN HEALTH
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
- (2011) F. Babakhani et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Treatment of refractory and recurrent Clostridium difficile infection
- (2011) Christina M. Surawicz et al. Nature Reviews Gastroenterology & Hepatology
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
- (2010) Stuart H. Cohen et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Economic healthcare costs of Clostridium difficile infection: a systematic review
- (2010) S.S. Ghantoji et al. JOURNAL OF HOSPITAL INFECTION
- A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
- (2010) G. W. Tannock et al. MICROBIOLOGY-SGM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now